A Comparison of Morphine and Morphine Plus Dexmedetomidine in Chronic Cancer Pain

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-11-30

Study Completion Date

2015-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether dexmedetomidine added to morphine is effective in the treatment of chronic cancer pain.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Switching From Morphine to Oral Methadone Plus Acetaminophen in the Treatment of Cancer Pain

NCT00525967

Cancer Pain Palliative Care

UNKNOWN PHASE2/PHASE3

IV Paracetamol, Dexketoprofen or Morphine for the Treatment of Low Back Pain

NCT01422291

Low Back Pain

COMPLETED PHASE4

Correlation Between the Analgesic Effect of Fentanyl Transdermal Patches and Nutritional Status in Cancer Pain Patients

NCT06369961

Cancer Pain Nutrition Disorders

COMPLETED

Dexmedetomidine Addition to Morphine in Patients With Metastatic Cancer

NCT03936205

Refractory Pain Metastatic Cancer

COMPLETED PHASE2/PHASE3

Efficacy and Safety of Ultra-low Dose Methadone as Adjuvant Analgesic in Cancer Patients With Pain

NCT02687347

Pain, Intractable

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

We conduct the study in Cukurova University Faculty of Medicine Research Hospital after obtaining ethics committee approval and patient's informed consent. Patients with cancer pain are allocated into two group to receive Patient Controlled Analgesia with morphine or morphine plus dexmedetomidine.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control

Morphine, 0.02 mg/kg PCA bolus dose with 10 minutes lock-out interval

Group Type ACTIVE_COMPARATOR

Morphine

Intervention Type DRUG

Morphine, 0.02 mg/kg PCA bolus dose with 10 minutes lock-out interval

Morphine plus dexmedetomidine

Morphine 0.02 mg/kg plus dexmedetomidine 0.1 microgram/kg PCA bolus dose with 10 minutes lock-out interval

Group Type ACTIVE_COMPARATOR

Morphine plus dexmedetomidine

Intervention Type DRUG

Morphine 0.02 mg/kg plus dexmedetomidine 0.1 microgram/kg PCA bolus dose with 10 minutes lock-out interval

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Morphine

Morphine, 0.02 mg/kg PCA bolus dose with 10 minutes lock-out interval

Intervention Type DRUG

Morphine plus dexmedetomidine

Morphine 0.02 mg/kg plus dexmedetomidine 0.1 microgram/kg PCA bolus dose with 10 minutes lock-out interval

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

morphine sulphate Morphine sulphate plus dexmedetomidine

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients with chronic cancer pain
* between 20-80 years old age

Exclusion Criteria

* the presence of severe systemic disease(cardiac, pulmonary, hepatic or renal)
* psychiatric or neurologic disease
* unable to communicate verbally
* nausea and vomiting
* patient's refusal

Minimum Eligible Age

20 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No